Author Topic: Natalizumab and liver injury research information (PubMed)  (Read 75 times)

0 Members and 2 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
Natalizumab and liver injury research information (PubMed)
« on: October 25, 2019, 07:56:09 pm »
The Overview section of segment on natalizumab in the report entitled "LiverTox: Clinical and research information on drug-induced liver injury" from the National Institute of Diabetes and Digestive and Kidney Diseases. There is apparently no "likelihood score" (defined as "likely cause of clinically apparent liver injury") included for natalizumab.


https://www.ncbi.nlm.nih.gov/books/NBK548623/#Natalizumab.OVERVIEW
« Last Edit: October 26, 2019, 05:59:43 am by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
140 Views
Last post October 24, 2019, 04:29:04 pm
by agate
0 Replies
156 Views
Last post October 26, 2019, 03:31:32 pm
by agate
0 Replies
97 Views
Last post October 26, 2019, 03:36:52 pm
by agate
0 Replies
132 Views
Last post October 26, 2019, 03:38:12 pm
by agate
0 Replies
138 Views
Last post October 28, 2019, 04:12:17 pm
by agate